Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Alexandria Real Estate Equities

BioCentury | Aug 19, 2023
Regulation

Aug. 18 Quick Takes: FDA approvals for Regeneron, Neurocrine  

Plus: Priority review for full approval of Calliditas’ Tarpeyo and updates from Astellas-Iveric, Merck, Arch newco TFC 
BioCentury | May 5, 2023
Discovery & Translation

J&J’s fusion protein for Staph infection; plus cGAS for Alzheimer’s and more

BioCentury’s roundup of translational news
BioCentury | Sep 1, 2022
Management Tracks

Accelerating talent out of academia

Nucleate and SPARK provide case studies in readying grad students and postdocs for industry
BioCentury | Nov 16, 2021
Product Development

Nov. 15 Quick Takes: $500M first close of CBC’s biotech facilities venture

Plus PhaseBio, Rhythm, PharmaEssentia and more
BioCentury | Jun 4, 2021
Emerging Company Profile

Stablix takes targeted protein degradation’s tactics in reverse

Emerging Company Profile: Versant’s protein stabilization play has $63M to develop ‘RESTORACS’ for rare diseases, cancer and autoimmunity
BioCentury | Dec 15, 2020
Finance

Westlake aims to strengthen L.A.-area biotech ecosystem with pair of new funds, new immunology launch

Seidenberg, Harper raise second flagship fund, separate vehicle for follow-on investments
BioCentury | Jul 3, 2019
Emerging Company Profile

Kymera: a systematic approach to protein degradation

Kymera goes beyond empirical approach to protein degradation with Pegasus platform
BioCentury | Jun 7, 2019
Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

How Alexandria became the most prolific life sciences VC
Items per page:
1 - 10 of 94